LGD-4033 is in a class of tissue receptors that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness, and age related muscle loss.
LGD-4033 is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.
Reviews
There are no reviews yet.